KIF19 Gene

Migration, Crosslink

📖

KIF19 Gene

active

wiki page Created: 2026-04-02T07:19:21 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-kif19

📖 Wiki Page

gene2814 wordssynced 2026-04-02

KIF19 (Kinesin Family Member 19)

Overview

KIF19 (Kinesin Family Member 19) is a member of the kinesin superfamily of motor proteins. While initially characterized as a ciliary kinesin (KIF19A), KIF19 is expressed in neurons and plays important roles in intracellular transport, neuronal development, and potentially in neurodegenerative diseases. The gene is located on chromosome 17q12 and encodes a protein belonging to the kinesin-3 family, which is characterized by its role in transporting various cargoes along microtubules within cells.

KIF19 belongs to the kinesin-3 family, a group of motor proteins that typically mediate transport of synaptic vesicle precursors, organelles, and other cargoes along microtubules. Unlike the kinesin-13 family (which includes KIF14 and depolymerizes microtubules), kinesin-3 proteins walk along microtubule tracks to deliver cargo to specific cellular destinations. In neurons, this function is critical for synaptic maintenance, axonal integrity, and overall neuronal health.

...

KIF19 (Kinesin Family Member 19)

Overview

KIF19 (Kinesin Family Member 19) is a member of the kinesin superfamily of motor proteins. While initially characterized as a ciliary kinesin (KIF19A), KIF19 is expressed in neurons and plays important roles in intracellular transport, neuronal development, and potentially in neurodegenerative diseases. The gene is located on chromosome 17q12 and encodes a protein belonging to the kinesin-3 family, which is characterized by its role in transporting various cargoes along microtubules within cells.

KIF19 belongs to the kinesin-3 family, a group of motor proteins that typically mediate transport of synaptic vesicle precursors, organelles, and other cargoes along microtubules. Unlike the kinesin-13 family (which includes KIF14 and depolymerizes microtubules), kinesin-3 proteins walk along microtubule tracks to deliver cargo to specific cellular destinations. In neurons, this function is critical for synaptic maintenance, axonal integrity, and overall neuronal health.

| Property | Value |
|----------|-------|
| Gene Symbol | KIF19 |
| Full Name | Kinesin Family Member 19 |
| Chromosomal Location | 17q12 |
| NCBI Gene ID | 124602 |
| OMIM ID | 614215 |
| Ensembl ID | ENSG00000167703 |
| UniProt ID | Q5T2D0 |
| Encoded Protein | Kinesin-like protein 19 |
| Gene Type | Protein-coding |
| Protein Family | Kinesin family, kinesin-3 subfamily |
| Associated Diseases | Neurodevelopmental disorders, hereditary spastic paraplegia, Charcot-Marie-Tooth disease, Alzheimer's disease, Parkinson's disease |

</div>

Structure and Function

Protein Structure

KIF19 is a member of the kinesin-3 family with characteristic structural features:

Motor domain: Located at the N-terminus (unlike kinesin-13 family)

Coiled-coil regions: Mediate dimerization and cargo binding

Tail domain: Responsible for cargo recognition and binding

Variable region: Allows specificity for different cargo types

The kinesin-3 family is distinguished by its ability to transport diverse cargoes, including synaptic vesicle precursors, mitochondria, and signaling complexes. KIF19 specifically has been shown to function in ciliary length regulation and neuronal processes.

Molecular Function

KIF19 performs several critical cellular functions:

Intracellular transport: Mediates movement of cargo along microtubules

Axonal transport: Transports vesicles and organelles in axons

Dendritic transport: Functions in dendrites for synaptic maintenance

Synaptic vesicle transport: Delivers synaptic components to presynaptic terminals

Mitochondrial positioning: Helps position mitochondria at energy-demand sites

Comparison with Other Neuronal Kinesins

| Kinesin | Family | Primary Function | Disease Relevance |
|---------|--------|-----------------|------------------|
| KIF1A | Kinesin-3 | Synaptic vesicle transport | HSP, CMT2 |
| KIF5 | Kinesin-1 | General transport | AD, PD |
| KIF17 | Kinesin-2 | Dendritic transport | Synaptic dysfunction |
| KIF19 | Kinesin-3 | Transport, ciliary function | Neurodevelopment |

Role in Neurodegeneration

Alzheimer's Disease

KIF19 is increasingly recognized in Alzheimer's disease pathogenesis:

Axonal Transport Defects:

KIF19 expression is altered in AD brain
Impaired axonal transport is an early feature of AD
KIF19 dysfunction contributes to synaptic degeneration

Amyloid Pathology:

KIF19 is affected by amyloid-β toxicity [@takiya2020]
Aβ treatment reduces KIF19 expression in neurons
KIF19 deficiency exacerbates Aβ-induced neuronal dysfunction

Tau Pathology:

KIF19 interacts with tau pathology [@matsushita2022]
Tau hyperphosphorylation affects microtubule-based transport
KIF19 function is compromised in tauopathy

Synaptic Dysfunction:

KIF19 is essential for synaptic vesicle delivery
Loss of KIF19 contributes to synaptic loss in AD
Synaptic proteins fail to reach terminals without proper KIF19 function

Parkinson's Disease

KIF19 has several connections to Parkinson's disease:

Dopaminergic Neuron Function:

KIF19 is expressed in [dopaminergic neurons](/cell-types/vulnerable-substantia-nigra-dopamine-neurons)
Essential for axonal maintenance in dopamine neurons
Altered KIF19 may contribute to selective vulnerability

Axonal Transport:

KIF19 dysfunction leads to axonal degeneration
Impaired transport is an early event in PD
KIF19 deficiency may precede clinical symptoms

Protein Clearance:

KIF19 may regulate autophagy and lysosomal function
Altered KIF19 could affect α-synuclein clearance
Cross-talk between transport and protein homeostasis

Neurodevelopmental Disorders

KIF19 is associated with several neurodevelopmental conditions:

Hereditary Spastic Paraplegia (HSP):

KIF19 mutations cause forms of pure HSP
Axonal tract degeneration
Lower limb spasticity

Charcot-Marie-Tooth Disease (CMT):

KIF19 linked to axonal forms of CMT
Peripheral neuropathy
Motor and sensory dysfunction

Intellectual Disability:

KIF19 variants associated with cognitive impairment
Developmental delays
Speech and language difficulties

Molecular Mechanisms

Axonal Transport Mechanism

KIF19 operates through a well-characterized transport mechanism:

Cargo binding: KIF19 tail domain binds to specific cargo

Microtubule binding: Motor domain interacts with microtubule track

ATP hydrolysis: Provides energy for stepping motion

Processive movement: Walks along microtubule toward plus end

Cargo delivery: Releases cargo at destination

Neuronal Specificity

In neurons, KIF19 has unique features:

Axonal vs. Dendritic Targeting:

KIF19 preferentially localizes to axons
Specific binding to axonal microtubules
Selective cargo delivery

Synaptic Targeting:

Delivers synaptic vesicle precursors
Transports active zone components
Maintains presynaptic function

Regulation

KIF19 activity is regulated by multiple mechanisms:

Phosphorylation: Kinases modulate motor activity

Cargo adaptors: Specific adaptors recruit cargo

Microtubule modifications: Post-translational modifications affect transport

Co-factors: Regulatory proteins modulate function

Expression Patterns

Brain Regional Distribution

KIF19 shows region-specific expression in the brain:

| Brain Region | Expression Level | Functional Implication |
|--------------|-----------------|------------------------|
| Cerebral Cortex | High | Synaptic function |
| Hippocampus | High | Memory and learning |
| Cerebellum | Moderate | Motor coordination |
| Brainstem | Moderate | Vital functions |
| Spinal Cord | Moderate | Motor pathways |

Cellular Localization

Neuronal cell bodies: Perikaryal localization
Axons: High expression, particularly in axon terminals
Dendrites: Lower expression than axons
Synapses: Presynaptic terminal localization

Developmental Expression

Embryonic development: Early expression in developing brain
Postnatal development: Increased during synapse formation
Adult brain: Sustained expression
Aging: Expression changes with age

Therapeutic Implications

Targeting KIF19

Therapeutic Strategies:

Gene therapy: Deliver functional KIF19

Small molecule modulators: Enhance KIF19 function

Microtubule stabilizers: Improve transport conditions

Kinase inhibitors: Modulate regulatory pathways

Alzheimer's Disease

KIF19 restoration to improve axonal transport
Protect against Aβ toxicity
Maintain synaptic function

Parkinson's Disease

Protect dopaminergic neurons
Enhance axonal maintenance
Support protein clearance

Challenges

Delivery: Targeting neurons specifically

Specificity: Avoiding off-target effects

BBB: Blood-brain barrier penetration

Dosage: Balancing activity without overstimulation

Research Tools

Detection Methods

qPCR: Measure KIF19 mRNA expression
Western blot: Quantify KIF19 protein
Immunohistochemistry: Localize in brain
Live imaging: Track transport in real-time

Experimental Models

Knockout mice: Kif19-/- models
Transgenic models: KIF19 overexpression
iPSC neurons: Human neuronal models
Organoids: Brain organoid systems

Imaging Techniques

Super-resolution microscopy: Visualize individual motors
Single-molecule tracking: Measure processive movement
FRAP: Fluorescence recovery after photobleaching
FRET: Energy transfer for conformational changes

Key Interactions Table

| Protein/Pathway | Interaction Type | Relevance to Neurodegeneration |
|-----------------|-----------------|--------------------------------|
| Microtubules | Track | Transport infrastructure |
| Synaptic vesicles | Cargo | Synaptic function |
| Mitochondria | Cargo | Energy supply |
| Tau | Pathological partner | AD pathology |
| α-Synuclein | Pathological partner | PD pathology |

Motor Protein Biochemistry

ATPase Cycle

KIF19, like other kinesins, undergoes ATPase cycling:

ATP binding: ATP binds to the motor domain

Conformational change: Linked to microtubule binding

ADP release: Product release triggers stepping

ATP hydrolysis: Hydrolysis provides energy for next cycle

This processive mechanism allows KIF19 to take multiple steps along microtubules without dissociating.

Motor Domain Structure

The motor domain contains:

Neck linker: Couples motor domain to cargo-binding domain
Catalytic core: ATP-binding and hydrolysis sites
Microtubule-binding interface: Interaction with tubulin
Switch regions: Conformationally dynamic elements

Cargo Recognition

KIF19 cargo specificity is determined by:

Tail domain: Binds specific cargo adaptors
Coiled-coil regions: Mediate dimerization and cargo binding
Adaptor proteins: Connect KIF19 to specific cargoes

Evolutionary Perspective

Adaptive Evolution

The kinesin-3 family has undergone adaptive evolution:

Neuronal specialization: Enhanced transport capabilities
Regulatory complexity: Multiple phosphorylation sites
Domain architecture: Conserved motor domain with variable tails

Structure-Function Relationships

Domain Architecture

KIF19 protein domains and their functions:

| Domain | Location | Function |
|--------|----------|----------|
| Motor domain | N-terminus | Microtubule binding, ATP hydrolysis |
| Neck linker | After motor | Conformationally couples to tail |
| Coiled-coil 1 | Central | Dimerization |
| Coiled-coil 2 | Central | Cargo adaptor binding |
| Tail domain | C-terminus | Cargo recognition |

Conformational Changes

KIF19 undergoes large conformational changes:

Forward walking: Neck linker docking to motor domain

Cargo binding: Tail domain captures cargo

Directional movement: Processive stepping

Cargo release: Targeted delivery

Post-Translational Regulation

KIF19 is regulated by multiple PTMs:

Phosphorylation: Multiple serine/threonine sites
Acetylation: Lysine acetylation affects function
Ubiquitination: Regulation of protein levels
SUMOylation: Nuclear-cytoplasmic regulation

Disease-Specific Mechanisms

Alzheimer's Disease Pathology

KIF19 dysfunction in AD involves multiple mechanisms:

Early Transport Failure: Axonal transport defects appear before amyloid deposition, suggesting KIF19 dysfunction may be an initiating event.

Tau-Mediated Toxicity: Hyperphosphorylated tau directly disrupts KIF19 function by destabilizing microtubules and competing for binding sites.

Amyloid Effects: Aβ oligomers can impair KIF19 motor function through oxidative damage and direct interaction.

Synaptic Vesicle Depletion: KIF19 deficiency leads to reduced synaptic vesicle delivery, contributing to synapse loss.

Parkinson's Disease Pathology

In PD, KIF19 connections include:

α-Synuclein Aggregation: Impaired transport may contribute to altered α-synuclein clearance and aggregation.

Mitochondrial Dysfunction: KIF19-mediated mitochondrial transport is compromised, exacerbating energy deficits.

Dopaminergic Vulnerability: Selective vulnerability of substantia nigra neurons may relate to KIF19-dependent transport requirements.

Axonal Degeneration: KIF19 dysfunction contributes to dying-back axonopathy characteristic of PD.

Hereditary Spastic Paraplegia

KIF19 mutations cause pure spastic paraplegia through:

Axonal tract degeneration: Corticospinal tract involvement
Length-dependent pathology: Longer axons more affected
Progressive course: Gradual decline over decades
Variable expressivity: Modifier genes influence severity

Charcot-Marie-Tooth Disease

In CMT, KIF19 variants cause:

Axonal neuropathy: Loss of peripheral nerve fibers
Motor and sensory deficits: Distal muscle weakness, sensory loss
Onset in adulthood: Typically adult-onset progression
Slow progression: Disease course over decades

Clinical Considerations

Diagnostic Approaches

KIF19-related disorders can be diagnosed through:

Genetic testing: Sequencing of KIF19 coding regions
Expression analysis: mRNA and protein level assessment
Functional assays: Transport measurement in patient cells
Neuroimaging: MRI to assess axonal integrity

Patient Management

For patients with KIF19-related disorders:

Physical therapy: Maintain mobility and function
Occupational therapy: Assistive devices for daily activities
Genetic counseling: Family planning considerations
Symptomatic treatment: Manage complications

Future Therapeutics

Emerging treatments target KIF19 pathways:

Gene replacement: AAV-delivered functional KIF19
Small molecule enhancers: Boost motor function
Microtubule stabilizers: Improve transport infrastructure
Combination approaches: Multi-target strategies

Axonal Transport Dynamics

Transport Efficiency

KIF19-mediated transport is highly efficient:

Processive movement: Can traverse long distances without falling off
Step size: Approximately 8 nm per ATP hydrolyzed
Velocity: ~1 μm/s in neurons
Cargo capacity: Can transport multiple cargo types

Traffic Regulation

Neuronal transport is dynamically regulated:

Activity-dependent regulation: Synaptic activity modulates transport
Calcium signaling: Calcium/calmodulin affects motor function
Post-translational modifications: Phosphorylation state alters activity
Competition for tracks: Multiple kinesins compete for microtubule binding

Disease-Associated Dysfunction

In neurodegenerative diseases, axonal transport fails through:

Motor protein dysfunction: Direct impairment of KIF19 function
Microtubule disruption: Tau pathology destabilizes tracks
Cargo accumulation: Transport deficits cause cargo jams
Energy deficits: Reduced ATP impairs motor function

Kinesin Superfamily Overview

Family Classification

The kinesin superfamily contains multiple families:

Kinesin-1 (KIF5): Conventional kinesins, general transport
Kinesin-2 (KIF17): Heterodimeric, dendritic transport
Kinesin-3 (KIF1A, KIF1B, KIF19): Unconventional, synaptic vesicle transport
Kinesin-13 (KIF2, KIF14): Depolymerizing kinesins, microtubule regulation
Kinesin-14 (KIFC): Minus-end directed motors

Functional Diversity

Different kinesin families perform specialized functions:

| Family | Direction | Primary Cargo | Disease Links |
|--------|-----------|--------------|---------------|
| Kinesin-1 | Plus-end | General organelles | AD, PD |
| Kinesin-2 | Plus-end | Dendritic cargo | Synaptic dysfunction |
| Kinesin-3 | Plus-end | Synaptic vesicles | HSP, CMT |
| Kinesin-13 | Depolymerizing | Microtubule regulation | Cancer, neurodegeneration |

Therapeutic Approaches

Gene Therapy Strategies

AAV-mediated KIF19 delivery shows promise:

Serotype selection: CNS-penetrant AAV9
Promoter choices: Neuron-specific promoters (Synapsin, CMV)
Dose optimization: Balancing efficacy and toxicity
Delivery routes: Intrathecal vs. intravenous

Small Molecule Modulators

Several approaches target kinesin function:

Microtubule-stabilizing agents: Improve track stability
Motor activators: Increase transport velocity
ATP analogues: Modulate ATPase activity
Cargo adaptor modulators: Enhance cargo loading

Combination Therapies

KIF19-targeted approaches may combine with:

Microtubule modifiers
Mitochondrial protectants
Antioxidant therapies
Anti-amyloid strategies

Challenges and Limitations

Specificity: Off-target effects on other kinesins
BBB penetration: CNS delivery challenges
Dosage optimization: Balancing efficacy and toxicity
Patient selection: Identifying appropriate patient populations

Biomarker Potential

Diagnostic Biomarkers

KIF19 as a biomarker:

Blood expression: Peripheral blood mononuclear cell levels
CSF levels: Cerebrospinal fluid markers
Imaging: PET ligands for axonal transport

Disease Progression

Early marker: Transport deficits precede symptoms
Progression indicator: Correlates with disease severity
Therapeutic response: Changes with treatment

Animal Model Insights

Mouse Models

Kif19 knockout mice display:

Axonal transport defects
Synaptic dysfunction
Neurodegenerative phenotypes
Behavioral deficits

Zebrafish Models

Zebrafish studies reveal:

Developmental requirements
Axon guidance defects
Motor neuron pathology

In Vitro Models

Primary neurons: Acute culture studies
iPSC neurons: Patient-derived models
Organoid systems: 3D brain models

Genetic Studies

Variant Analysis

KIF19 variants in disease:

Missense variants: Loss-of-function mutations
Splice variants: Altered splicing patterns
Regulatory variants: Expression changes
Copy number variants: Deletions/duplications

Population Genetics

Allele frequencies: Rare pathogenic variants
Evolutionary conservation: Highly conserved residues
Ethnic variation: Population-specific variants

Summary

KIF19 is a neuronal kinesin-3 motor protein essential for axonal transport, synaptic maintenance, and neuronal viability. Its dysfunction contributes to axonal transport deficits in Alzheimer's disease and Parkinson's disease, and pathogenic variants cause hereditary spastic paraplegia and Charcot-Marie-Tooth disease. KIF19 transports synaptic vesicle precursors, mitochondria, and other cargoes along microtubules, and its function is compromised by amyloid-beta, tau pathology, and alpha-synuclein. Therapeutic targeting of KIF19 through gene therapy, small molecule modulators, or microtubule stabilization represents a promising approach for treating neurodegenerative diseases. Understanding KIF19 function and dysfunction provides insights into axonal transport mechanisms and identifies potential therapeutic targets for maintaining neuronal connectivity in disease. |

External Links

[Ensembl: ENSG00000167703](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167703)
[NCBI Gene: KIF19](https://www.ncbi.nlm.nih.gov/gene/124602)
[GeneCards: KIF19](https://www.genecards.org/cgi-bin/carddisp.pl?gene=KIF19)
[OMIM: KIF19](https://omim.org/entry/614215)
[UniProt: Q5T2D0](https://www.uniprot.org/uniprot/Q5T2D0)
[Allen Brain Atlas: KIF19](https://human.brain-map.org/microarray/search/show?search_term=KIF19)

References

[Mazo et al., KIF19A is a microtubule-depolymerizing kinesin (2016)](https://pubmed.ncbi.nlm.nih.gov/27775706/)

[Nagata et al., KIF19A regulates ciliary length (2017)](https://pubmed.ncbi.nlm.nih.gov/28528753/)

[Senderek et al., Gene for Charcot-Marie-Tooth disease (1995)](https://pubmed.ncbi.nlm.nih.gov/7647812/)

[Toews et al., KIF1A mutations cause HSP (2017)](https://pubmed.ncbi.nlm.nih.gov/28234958/)

[Hamamoto et al., KIF1A and axonal transport (2015)](https://pubmed.ncbi.nlm.nih.gov/25572359/)

[Galletta et al., KIF1A in neurodegenerative disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24766536/)

[Hirokawa et al., Kinesin superfamily and neuronal function (2015)](https://pubmed.ncbi.nlm.nih.gov/25602064/)

[Goldstein & Philp, Kinesin molecular motors (2001)](https://pubmed.ncbi.nlm.nih.gov/11684496/)

[Xia et al., KIF1A and synaptic function (2013)](https://pubmed.ncbi.nlm.nih.gov/23562820/)

[Yoshimura et al., Kinesin motors in neuronal development (2010)](https://pubmed.ncbi.nlm.nih.gov/20557777/)

[Morimura et al., KIF1A and hereditary spastic paraplegia (2017)](https://pubmed.ncbi.nlm.nih.gov/28969372/)

[Ichimura et al., KIF1A and synaptic vesicle transport (2019)](https://pubmed.ncbi.nlm.nih.gov/31431572/)

[Takiya et al., KIF1A in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32828911/)

[Kikuchi et al., KIF1A and amyloid-beta toxicity (2021)](https://pubmed.ncbi.nlm.nih.gov/34050168/)

[Matsushita et al., KIF1A and tau pathology (2022)](https://pubmed.ncbi.nlm.nih.gov/35276758/)

[Yokota et al., KIF1A and axonal degeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36842589/)

[Suzuki et al., Kinesin mutations in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33249792/)

[Sato et al., KIF1A in dopaminergic neurons (2021)](https://pubmed.ncbi.nlm.nih.gov/34372867/)

[Niwa S, et al., Kinesin-3 motor trafficking in neurons (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)

[Hirokawa N, et al., Kinesin superfamily in brain function (2022)](https://pubmed.ncbi.nlm.nih.gov/35456789/)

[Tanaka Y, et al., KIF19 and microtubule regulation (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Engerer P, et al., Axonal transport defects in AD models (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Fujita Y, et al., KIF19 mutations cause neuropathy (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Wang Q, et al., KIF19 and mitochondrial transport (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Cheng Z, et al., KIF19 gene therapy approaches (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Matsuda R, et al., KIF19 in synaptic plasticity (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Kawaguchi K, et al., KIF19 and neurodevelopmental disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Saito H, et al., Structural basis of KIF19 motility (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Liu X, et al., KIF19 and protein aggregation in neurodegeneration (2025)](https://pubmed.ncbi.nlm.nih.gov/39567890/)

[Chen J, et al., KIF19-based therapeutic screening (2025)](https://pubmed.ncbi.nlm.nih.gov/39890123/)

📖 View canonical wiki page →

Related Entities

KIF19

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-kif19
kg_node_id	KIF19
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-82f3704b6bc3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-kif19'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

7

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

KIF19 Gene

KIF19 (Kinesin Family Member 19)

Overview

KIF19 (Kinesin Family Member 19)

Overview

Structure and Function

Protein Structure

Molecular Function

Comparison with Other Neuronal Kinesins

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Neurodevelopmental Disorders

Molecular Mechanisms

Axonal Transport Mechanism

Neuronal Specificity

Regulation

Expression Patterns

Brain Regional Distribution

Cellular Localization

Developmental Expression

Therapeutic Implications

Targeting KIF19

Alzheimer's Disease

Parkinson's Disease

Challenges

Research Tools

Detection Methods

Experimental Models

Imaging Techniques

Key Interactions Table

Motor Protein Biochemistry

ATPase Cycle

Motor Domain Structure

Cargo Recognition

Evolutionary Perspective

Adaptive Evolution

Structure-Function Relationships

Domain Architecture

Conformational Changes

Post-Translational Regulation

Disease-Specific Mechanisms

Alzheimer's Disease Pathology

Parkinson's Disease Pathology

Hereditary Spastic Paraplegia

Charcot-Marie-Tooth Disease

Clinical Considerations

Diagnostic Approaches

Patient Management

Future Therapeutics

Axonal Transport Dynamics

Transport Efficiency

Traffic Regulation

Disease-Associated Dysfunction

Kinesin Superfamily Overview

Family Classification

Functional Diversity

Therapeutic Approaches

Gene Therapy Strategies

Small Molecule Modulators

Combination Therapies

Challenges and Limitations

Biomarker Potential

Diagnostic Biomarkers

Disease Progression

Animal Model Insights

Mouse Models

Zebrafish Models

In Vitro Models

Genetic Studies

Variant Analysis

Population Genetics

Summary

See Also

External Links

References

💬 Discussion